Mon, Apr 21, 2014, 2:29 AM EDT - U.S. Markets open in 7 hrs 1 mins

Recent

% | $
Quotes you view appear here for quick access.

Apple Inc. (AAPL) Message Board

mugardisgreat 118 posts  |  Last Activity: Apr 15, 2014 10:09 AM Member since: Jul 28, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • mugardisgreat by mugardisgreat Apr 15, 2014 10:09 AM Flag

    MuGard
    received 510(k) clearance from the U.S. Food and Drug Administration and is
    marketed by AMAG Pharmaceuticals, Inc. in the United States, RHEI
    Pharmaceuticals in China, and Hanmi Pharmaceuticals in Korea.

  • Great but where is the european partnership that davis poromised

  • Access Pharmaceuticals Provides Update On Development Of LexaGard, A Proprietary Formulation Of Amlexanox

    Additional Mucoadhesive Polymer Hydrogel Technology Formulation; Seeking Marketing Partners

  • mugardisgreat by mugardisgreat Apr 3, 2014 8:31 PM Flag

    87% of smart phone profits THE NEW iPHONE 6 WILL BE HIGHER PRICE

    Sentiment: Strong Buy

  • mugardisgreat by mugardisgreat Apr 3, 2014 8:29 PM Flag

    Profit share versus market share
    Market share can be a poor measure of business health. While the majority of smartphone growth is in the low end of the market, the profits are in the high end. According to Raymond James, the iPhone now accounts for 87% of smartphone profits. Given the results of 5s and 5c sales, the creation a super-premium smartphone segment is a logical move for Apple.

    Foolish takeaway
    Sales results of the 5c and 5s underscore the willingness of Apple customers to pay a premium for a smartphone, provided there is clear differentiation in material and functionality. The release of a larger-screen iPhone with sapphire glass provides the opportunity to create a higher-priced segment for the iPhone, increasing revenue, margins, and profit share for the company.

    Sentiment: Strong Buy

  • MORE PRODUCTS TO SELL
    .

    ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided investors with a
    strategic update on its programs and plans for its proprietary mucoadhesive
    hydrogel platform technology. Access' patented technology surrounds a unique
    aqueous pseudoplastic liquid with a defined viscosity range, which is
    beneficial to the treatment of disorders of mucosal tissue, and includes the
    ability to act as a delivery system for a variety of active agents, including
    drugs.

    The mucoadhesive hydrogel technology is the basis for its product MuGard®
    which is indicated for conditions of the oral mucosa, including oral
    mucositis, and Access Pharmaceuticals is expanding its potential application
    in other mucosal tissues including the esophagus, the lower intestinal tract
    and the #$%$. The Company is exploring formulations with active agents that
    may include anesthetics, such as benzocaine, anti-fungal agents,
    anti-inflammatory drugs and medical foods and supplements. Combinations of
    Access' technology and active agents could take advantage of expedited
    regulatory pathways, such as the 505(b)(2) and 510(k) pathways, and offer
    extended patent protection for generic agents or those soon to lose patent
    protection.

    "Access has recently filed for expanded patent protection of its
    mucoadhesive polymer hydrogel technology and is engaged with regulatory
    consultants and bodies on the identification of appropriate pathways for a
    number of MuGard® follow-on products," stated Jeffrey B. Davis, President and
    CEO of Access Pharmaceuticals, Inc. "The recently announced ProctiGard(TM)
    program, for radiation proctitis, is the first of a number of product
    programs that highlights the power of this drug delivery platform

  • mugardisgreat by mugardisgreat Apr 1, 2014 8:42 AM Flag

    GOOD NEWS Lets hope they can get new PARTNERS for this new application it opens a huge new market for greatly increased sales, however as with every news release WE NEED OUTSIDE COMFORMATION AND THAT WILL BE BELIEVABLE WHEN WE GET PAYING PARTNERS.

    COBALAMIN IS VERY EXCITING BUT WE NEED A PARTNER WHO PAYS FOR THE LICENSE BEFORE WE KNOW ITS TRUE VALUE

    Sentiment: Strong Buy

  • mugardisgreat by mugardisgreat Apr 1, 2014 8:22 AM Flag

    ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided investors with a
    strategic update on its programs and plans for its proprietary mucoadhesive
    hydrogel platform technology. Access' patented technology surrounds a unique
    aqueous pseudoplastic liquid with a defined viscosity range, which is
    beneficial to the treatment of disorders of mucosal tissue, and includes the
    ability to act as a delivery system for a variety of active agents, including
    drugs.

    The mucoadhesive hydrogel technology is the basis for its product MuGard®
    which is indicated for conditions of the oral mucosa, including oral
    mucositis, and Access Pharmaceuticals is expanding its potential application
    in other mucosal tissues including the esophagus, the lower intestinal tract
    and the #$%$. The Company is exploring formulations with active agents that
    may include anesthetics, such as benzocaine, anti-fungal agents,
    anti-inflammatory drugs and medical foods and supplements. Combinations of
    Access' technology and active agents could take advantage of expedited
    regulatory pathways, such as the 505(b)(2) and 510(k) pathways, and offer
    extended patent protection for generic agents or those soon to lose patent
    protection.

    "Access has recently filed for expanded patent protection of its
    mucoadhesive polymer hydrogel technology and is engaged with regulatory
    consultants and bodies on the identification of appropriate pathways for a
    number of MuGard® follow-on products," stated Jeffrey B. Davis, President and
    CEO of Access Pharmaceuticals, Inc. "The recently announced ProctiGard(TM)
    program, for radiation proctitis, is the first of a number of product
    programs that highlights the power of this drug delivery platform."

  • mugardisgreat by mugardisgreat Mar 29, 2014 11:18 AM Flag

    "It is known that certain diseased cells, notably cancer, have an elevated demand for certain vitamins, including vitamin B12, making our Cobalamin platform technology compelling for reformulations of cancer-killing agents nearing the end of their patent life," stated Jeffrey B. Davis, President and CEO of Access Pharmaceuticals, Inc. "As pharmaceutical companies seek ways to create new formulations for the active drugs, and extend their patent runway, we believe our CobaCyte™ platform technology can be the necessary enabling technology."

    Access' worldwide-exclusive patented Cobalamin™ technology utilizes the body's natural vitamin B12 uptake mechanisms to facilitate absorption of pharmaceuticals and other active agents via a "Trojan horse" mechanism. Cobalamin transport can be amplified by the use of proprietary nanoparticles or polymers that can greatly amplify uptake. This technology platform provides Access with the ability to develop different formulations with improved benefits for various disease applications. The Company believes its Cobalamin drug delivery technology has broad application to proteins, small molecule drugs, hormones and potentially sRNAi therapeutics, and has recently accelerated its corporate partnering efforts around the technology.

    Abraxane® is a registered trademark of Celgene Corporation

  • NEW YORK, March 26, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (ACCP), an emerging biotechnology company, announced today that it is leveraging its proprietary CobaCyte™ drug delivery platform technology to create new formulations of active pharmaceutical agents. Access recently submitted an additional patent application to protect improvements in the technology and expand applications, and is actively seeking development partners globally. Access compared single doses of Cobraxane™, its proprietary nanoparticle formulation of commercially available protein-bound paclitaxel, with Abraxane® in a standard mouse tumor model. At a dose of Cobraxane™ which was half that of the maximum tolerated dose (MTD) of the standard paclitaxel particles, Cobraxane™ demonstrated slightly better tumor growth inhibition than the MTD dose of standard paclitaxel particles. Cobraxane™, injected at the same dose as the MTD dose of standard paclitaxel particles, provided significantly better tumor growth inhibition than the MTD dose of standard paclitaxel particles. Tumor shrinkage was observed at the higher dose of Cobraxane™. Access believes the preclinical data observed is a strong indicator of potential clinical and commercial value of Cobraxane™.

    Sentiment: Strong Buy

  • mugardisgreat by mugardisgreat Mar 27, 2014 4:39 PM Flag

    He manages $! TRILLION DOLLARS and his best pick is AAPL Talks about FREE CASH FLOW
    Maintains AAPL IS WORTH $700 NOW AND WILL GROW EACH YEAR
    Laughs at the TRADERS AND THEIR NONSENSE
    AAPL IS THE BEST INVESTMENT

  • mugardisgreat by mugardisgreat Mar 26, 2014 5:05 PM Flag

    "As pharmaceutical companies seek ways to create new formulations for the active drugs, and extend their patent runway, we believe our CobaCyte™ platform technology can be the necessary enabling technology."



    THE ABOVE STATEMENT TELLS THE STORY ACCP IS TAKING APPROVED DRUGS WRAPING THEM IN THEIR COBALAMIN VITAMIN B 12 SO THE COMBINATION HAS A HIGHER ATTRACTION TO CANCER CELLS



    Now that combination is INJECTED and because of the vitamin b 12 wrap it delivers more of the drug directly to the cancer cells without the damage to other healthy cells



    BY PUTTING THE DRUG INTO THIS WRAP IT BECOMES A NEW ITEM WITH A NEW PATENT LIFE



    IF THIS WORKS ITS HUGE WITHOUT THE PROBLEMS OF TRYING TO GET A INJECTABLE TO BECOME ORAL WHICH IS ALSO A BIG DEAL BUT HAS TAKEN A LONG TIME TO CONTROL THE DOSAGE AS ITS ABSORBED TRRU THE GUT.



    There are many CANCER DRUGS COMING OFF PATENT THAT CAN HAVE A NEW LIFE UNDER THIS NEW DELIVERY SYSTEM



    AS BEFORE I NEED TO SEE A THIRD PARTY PHARMA COMPANY CONFIRM THIS AND THE BEST WAY THAT WILL BECOME BELIVABLE IS A PAYING PARTNERSHIP SOMETHING THAT HAS NOT HAPPENED YET

    Sentiment: Strong Buy

  • mugardisgreat by mugardisgreat Mar 26, 2014 8:52 AM Flag

    Access Pharmaceuticals Cobraxane™ Offers Enhanced Tumor Growth Inhibition In Tumor Models

  • mugardisgreat by mugardisgreat Mar 26, 2014 8:50 AM Flag

    See how COBALAMIN THAKES EXISTING APPROVED drugs and makes them more powerful and THEN THEY HAVE A NEW PATENT LIFE
    IF PARTNERED THIS WILL BE HUGE

  • mugardisgreat by mugardisgreat Mar 26, 2014 8:37 AM Flag

    Access Pharmaceuticals Cobraxane™ Offers Enhanced Tumor Growth Inhibition In Tumor Models

  • mugardisgreat by mugardisgreat Mar 26, 2014 8:36 AM Flag

    read about ACCP looking for partners now and COBALAMIN extends other working drugs pattern life

  • mugardisgreat by mugardisgreat Mar 23, 2014 7:13 AM Flag

    4 Week Price % Change 64.25%


    13 Week Price % Change 135.20%


    26 Week Price % Change 45.19%


    52 Week Price % Change 10.94%

    YTD Week Price % Change 135.20%

  • mugardisgreat by mugardisgreat Mar 22, 2014 9:12 PM Flag

    TAKING ID AND CHANGING A LETTER you are one sick a hole

  • mugardisgreat by mugardisgreat Mar 22, 2014 9:03 PM Flag

    STINKY

  • mugardisgreat by mugardisgreat Mar 22, 2014 6:14 PM Flag

    ITS TIME to replay the STINKY CARTOON VIDEO

AAPL
524.94+5.93(+1.14%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.